Biogest is a prescription medication indicated for the management of symptoms associated with specific conditions related to hormonal imbalance in women. It provides therapeutic support for both acute issues and long-term maintenance requirements.

Quick Fact: Relief for Secondary Amenorrhea

The primary treatment areas include supporting embryo implantation and early pregnancy as part of an Assisted Reproductive Technology (ART) treatment program, managing secondary amenorrhea (absence of menstruation), and preventing endometrial hyperplasia in women undergoing hormone replacement therapy with estrogen. The goal of therapy is to help restore or maintain necessary hormone levels to promote clinical comfort and functional well-being.

Biogest is a key component in therapeutic strategies designed to address deficiencies in the hormone progesterone.

Eligibility and Contraindications

The eligibility profile for Biogest (Micronised Progesterone) is strictly defined by government regulatory documentation. The medicine is primarily approved for use in Adult Women, including non-hysterectomized women receiving estrogen hormone replacement therapy and women with secondary amenorrhea.

Classification	Official Regulatory Determination
Absolute Contraindications	Prohibited for patients with Known Hypersensitivity to any component (including peanut/soy oil in some formulations), Undiagnosed Abnormal Genital Bleeding, Known or Suspected Breast Cancer, Active or History of Thromboembolic Disorders (e.g., DVT, stroke), and Known Liver Dysfunction or Disease [FDA Label, SmPC-UK, DailyMed].
Age-Related Status	Pediatric Use is Not Indicated as safety and efficacy have Not Been Established. Geriatric use requires caution due to higher baseline risk in older adults [DailyMed].
Physiological/Condition Restrictions	Pregnancy use is Restricted to specific indications like Luteal Phase Support in ART. Use is Not Recommended during Lactation. Caution and close monitoring are required for patients with conditions like renal dysfunction, heart disease, or history of depression [SmPC-UK].

These regulatory classifications ensure the medicine is restricted to patient groups for whom the safety and efficacy profile is established and documented in the official labeling.

Biogest (micronised progesterone) has officially documented interaction patterns that primarily involve pharmacokinetic and pharmacodynamic mechanisms. Co-administration with potent Enzyme Inducers, such as rifampicin and certain barbiturates, may increase the clearance and metabolism of progesterone, which can reduce its effectiveness. Conversely, agents classified as CYP3A4 Inhibitors, including ketoconazole, may increase the bioavailability and exposure of progesterone.

The substance's absorption is highly dependent on co-ingestion factors. Because the concomitant ingestion of food increases the bioavailability of orally administered micronised progesterone, regulatory labels establish a timing rule that the medicine must not be taken with food. Additionally, alcohol abuse may similarly increase the bioavailability of progesterone. Certain antibiotics, such as ampicillin and tetracyclines, may affect the enterohepatic circulation of the steroid.

A key pharmacodynamic interaction noted in regulatory labeling concerns glucose tolerance. Progesterone may cause a reduction in glucose tolerance, potentially leading to an increased requirement for antidiabetic agents in the diabetic patient population. Furthermore, the product component itself dictates a restriction: the capsule is formally contraindicated in individuals with a known hypersensitivity to the excipient peanut oil (or soya).

Biogest is an exogenous source of micronized progesterone, a steroid hormone. The compound acts as an agonist at the intracellular progesterone receptors (PRs), which are primarily expressed in the female reproductive tissues, notably the endometrium and myometrium.

Upon binding of progesterone, the activated PRs dimerize and translocate to the cell nucleus, where they bind to specific Progesterone Response Elements (PREs) in the promoter regions of target genes. This molecular interaction modulates gene transcription, leading to the synthesis of specific proteins. The intracellular consequences include the promotion of secretory differentiation in the endometrial stroma and glandular tissue, which shifts the tissue from a proliferative to a secretory phase. In the myometrium, this signaling cascade results in the reduction of excitability and inhibition of contractile activity by altering ion channel function and decreasing the expression of contraction-associated proteins. System-level physiological consequences involve a shift in the endocrine balance, mimicking the functional effects of the endogenous luteal phase.

Biogest, a micronised progesterone soft gelatin capsule, is administered via the oral route in established dosing regimens. The medicine is available in strengths of 100 mg and 200 mg. Use is generally prescribed following a predetermined schedule, either as a fixed short-term course or as a cyclic regimen for long-term use.

---

Official Dosing and Use Patterns

Dosing Schedule	Regimen	Frequency & Duration
Endometrial Protection	200 mg administered daily.	Cyclic (e.g., 12 consecutive days per 28-day cycle).
Secondary Amenorrhea	400 mg administered daily.	Fixed Course of 10 consecutive days.
Alternative Cyclic Use	100 mg administered daily.	Continuous Sequential (e.g., Day 1 to Day 25 of a therapeutic cycle).

---

Standard administration specifies that the capsule should be taken as a single daily dose at bedtime (qHS). Food intake is associated with an increase in the systemic absorption of the active ingredient, though specific instructions on co-administration with food may vary. The medicine is intended to be swallowed whole. For individuals experiencing difficulty swallowing, it is recommended to take the capsule with water while maintaining an upright or standing position. Regarding specific populations, the medicine is not recommended for use in the pediatric population, while dosing for older adults is typically aligned with adult regimens.

---

Resulting Procedural Structure

The use protocol centers on daily oral ingestion of the prescribed capsule strength following a scheduled cycle or a short, fixed duration. Administration occurs at bedtime, and the capsule is to be swallowed without alteration, with consideration for posture during intake. This structured approach defines the standardized protocol for the medicine.

Research Evidence: Overview of Studies for Biogest

Evidence for Luteal Phase Support in Assisted Reproductive Technology (ART)

Research exploring the medicine's role in Luteal Phase Support (LPS) has primarily relied upon large-scale Randomized Controlled Trials (RCTs) and systematic reviews. These studies was studied for women undergoing various Assisted Reproductive Technology procedures, such as IVF or frozen embryo transfer (FET). Researchers monitored high-level clinical endpoints, including the Live Birth Rate and the Clinical Pregnancy Rate, which are outcomes related to systemic or functional imbalance in reproduction. Studies describe patterns observed in the studies related to these important pregnancy outcomes when the medicine was observed in the early phase of pregnancy.

Evidence for Endometrial Protection in Hormone Replacement Therapy (HRT)

The evidence base for this indication was evaluated in postmenopausal women who had not had a hysterectomy and were receiving estrogen therapy. The studies research examined the medicine's role in counterbalancing the effects of estrogen and preventing changes to the uterine lining, which are outcomes related to physical discomfort and functional imbalance. Studies reported that the medicine was associated with the necessary transformation of the uterine lining, moving from a proliferative state to a secretory state, as required by the study design. A key research limitation is that findings are typically derived from studies where the medicine was associated with an estrogen component as part of a combined treatment regimen.

Extended-Duration Research and Long-Term Follow-up

Across all indications, the follow-up durations were limited in the core clinical trials designed for regulatory submission. Research describes patterns observed in the studies but also clarifies that the durability of response and extended patient-reported outcomes describing perceived discomfort are not fully established in long-term observational settings. Evidence is limited for long-term outcomes across all indications, meaning that long-term effects are not fully established.

Research Gaps and Areas of Uncertainty

This final section synthesizes the limitations consistently seen across the various research programs. Comparative evidence is lacking for the medicine with other similar treatments in several contexts. Additionally, the results apply only to the populations studied, and there is acknowledged variability across studies when comparing different routes of administration, which means that certainty remains low on specific comparative factors.

Common questions about Biogest (FAQ)

---

Q: How does Biogest differ from other commonly known medicines used for similar conditions?

A: Official product information describes Biogest as containing micronized progesterone, which is a bioidentical compound. This compound has a chemical structure that is identical to the progesterone naturally produced by the human body. This differentiates the preparation from synthetic compounds known as progestins, which have a modified chemical structure.

Q: Do the side effects of Biogest tend to lessen or disappear over time?

A: Official regulatory information indicates that some common side effects, such as drowsiness and dizziness, are often transient or temporary. These effects are typically reported more frequently when patients first begin taking the medicine.

Q: Are there any specific dietary considerations or restrictions while using Biogest?

A: Regulatory documents note that because taking the capsule with food increases its absorption, the medicine is generally instructed not to be taken with food. Additionally, some official sources indicate that the consumption of grapefruit juice may need to be limited, as it can further increase the absorption of progesterone.

Q: Does Biogest interact with common herbal supplements like St. John's Wort?

A: Official drug safety warnings note that certain herbal products, such as those containing St. John's Wort, may interact with Biogest. St. John's Wort may increase the metabolism of progesterone, potentially leading to reduced effectiveness and lower blood levels.

Q: Can Biogest affect a patient's mood or mental state?

A: Regulatory documents note that the medicine may cause effects on the central nervous system, including dizziness and drowsiness. Official prescribing information also cautions that close monitoring is appropriate for patients with a history of depression or other psychiatric conditions.

Q: Does Biogest affect a patient's ability to drive or operate machinery?

A: Regulatory guidance indicates that patients are advised to use caution when driving or operating heavy machinery, especially when first starting treatment, due to the potential for dizziness or drowsiness.

Q: Why might a patient report that Biogest did not work for them?

A: Studies and official information indicate that the effectiveness can vary due to several factors. Other medicines, known as enzyme inducers, can increase the clearance of progesterone from the body, potentially reducing its effect. Additionally, individual differences in how a patient absorbs and metabolizes the medicine can lead to varying outcomes.

Q: What kind of studies examine the use of Biogest across different age groups?

A: Clinical research for the medicine has primarily focused on adult women, including premenopausal women participating in Assisted Reproductive Technology procedures. Studies also examine its use in postmenopausal women receiving hormone replacement therapy. Safety and efficacy have not been established for use in the pediatric population.

Q: Do patients with a history of heart conditions need to avoid Biogest?

A: Official regulatory documents indicate that the medicine is formally contraindicated (should not be used) for patients with a history of active thromboembolic disorders, such as a blood clot in the lung or a stroke. Caution and close monitoring are also required for patients with pre-existing heart disease due to the potential for fluid retention.

Q: Is Biogest available in a generic version?

A: Yes, official regulatory information confirms that the active ingredient, micronized progesterone, is available under Abbreviated New Drug Applications (ANDA). This status indicates that generic versions of the capsule are officially approved by government bodies and available for use.

Q: Can Biogest cause weight changes, such as weight gain or loss?

A: According to the official prescribing information, weight gain or weight loss are generally not listed among the adverse reactions classified as common. The regulatory documents categorize side effects based on how frequently they are reported in clinical studies.

Q: Does Biogest interact with common over-the-counter pain relievers?

A: Official interaction studies have not reported any clinically significant interactions between progesterone capsules and common pain relievers like acetaminophen (Tylenol). Patients are generally advised to discuss all combined medicines, including over-the-counter products, with a healthcare professional.

Q: Where can I find the results of the official clinical trials for Biogest?

A: The summary of the key clinical trial data and the full regulatory prescribing information used for official approval is made available by government bodies. This information can typically be accessed directly through the public-facing websites of regulatory authorities like the FDA (Food and Drug Administration) or the EMA (European Medicines Agency).

Q: What happens in the body when Biogest is stopped after extended use? (Non-directive)

A: Official safety information notes that discontinuing the medicine suddenly may cause certain effects, including increased anxiety and moodiness. In some contexts, it may increase the risk of having seizures. Any changes to the treatment plan should be discussed with the prescribing doctor.

Q: Is Biogest a controlled substance in the country of origin?

A: No, according to the official regulatory classification, the medicine is not classified as a scheduled (controlled) substance. This determination is typically made by governmental agencies such as the U.S. Drug Enforcement Administration (DEA) or equivalent bodies.

Q: What makes Biogest a prescription-only medicine?

A: The medicine is restricted to prescription use because it requires medical supervision to ensure safe administration. This supervision is necessary to monitor for serious potential adverse reactions, such as the risk of blood clots (thromboembolic disorders), and to ensure the patient does not have underlying contraindications like liver disease.

Q: What should be done if a scheduled time for using Biogest is missed? (Clarification, not instruction)

A: Official guidelines for a missed dose generally advise taking the capsule as soon as it is remembered, then continuing with the regular schedule. However, patients are cautioned against taking a double dose to compensate for a single missed one. Specific guidance should be followed as directed by a healthcare professional.

Q: How long does Biogest typically remain detectable in a person's system?

A: Pharmacokinetic studies indicate that the elimination half-life of orally administered micronized progesterone is generally reported to be in the range of 5 to 10 hours. This duration can vary based on factors such as whether the capsule was taken with food, which affects its absorption.

Q: Is it necessary to have certain tests done before starting Biogest?

A: Official prescribing information does not mandate the same specific tests for every patient before starting treatment. However, it notes that certain diagnostic procedures, such as blood pressure checks and liver function tests, may be performed both before starting and periodically during treatment to monitor health status.

How to Store and Dispose of Biogest?

The storage and disposal of Biogest (micronised progesterone capsules) are strictly defined by regulatory requirements to maintain product quality and ensure safety.

Storage Conditions

The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. It is mandatory to keep the capsules in the original, tightly closed container and protect them from light and moisture. Do not freeze the product under any circumstances. As with all medicines, Biogest must be kept out of the reach and sight of children.

Disposal Requirements

Dispose of any unused or expired capsules by utilizing a local drug take-back program. Medicines should not be disposed of via wastewater (flushing down the toilet or pouring down the sink) unless explicitly instructed by a regulatory authority. Follow local pharmaceutical waste instructions for proper disposal.